The FDA approved iptacopan (Fabhalta) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare but potentially fatal disorder affecting red blood cells (RBCs), ...
MONTREAL, April 14, 2025 /CNW/ - Novartis Canada is pleased to announce that Fabhalta ® (iptacopan capsules) is now available across Canada for adult patients with paroxysmal nocturnal hemoglobinuria ...
The U.S. FDA has approved Novartis AG’s Fabhalta (iptacopan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria, a rare blood disease that impairs blood cell production.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results